Rybelsus side effects: what the label reports, when they show up, and what counts as long-term

Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. It does not tell you to start, stop, pause, or change the dose of anything — those decisions belong to the clinician who wrote your prescription. If a symptom frightens you, contact them or emergency services rather than reading further.

Quick answer

In the FDA label's placebo-controlled pool, the most common Rybelsus side effects were nausea (20% at 14 mg, 11% at 7 mg, 6% placebo), abdominal pain, diarrhea, decreased appetite, vomiting and constipation. The label also states plainly that most nausea, vomiting and diarrhea reports occurred during dose escalation.

Open Takely in your browser

The frequencies, as the label prints them

Table 2 of the label reports adverse reactions that occurred in at least 5% of patients on semaglutide tablets and more often than on placebo, drawn from two placebo-controlled trials in adults with type 2 diabetes — 1,071 patients exposed to semaglutide tablets, mean exposure 41.8 weeks.

Adverse reaction	Placebo (N=362)	Rybelsus 7 mg (N=356)	Rybelsus 14 mg (N=356)
Nausea	6%	11%	20%
Abdominal pain	4%	10%	11%
Diarrhea	4%	9%	10%
Decreased appetite	1%	6%	9%
Vomiting	3%	6%	8%
Constipation	2%	6%	5%

Two things are worth noticing before moving on. Nausea roughly doubles between 7 mg and 14 mg while diarrhea barely moves — the dose relationship is not uniform across symptoms. And the placebo column is not zero: 6% of people who took no drug at all reported nausea. The honest reading of any single row is "how much more likely than nothing," not "how likely."

Below the 5% line, the label lists further gastrointestinal reactions with their frequencies given as 14 mg, 7 mg and placebo respectively: abdominal distension (3%, 2%, 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%).

Taken as a group, gastrointestinal reactions occurred in 41% of patients on 14 mg once daily, 32% on 7 mg, and 21% on placebo. Severe gastrointestinal reactions were reported in 2.0%, 0.6% and 0.3% respectively.

The dose-escalation pattern

This is the sentence most summaries leave out, and it is the one that changes how the first months read:

The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation.

Rybelsus titrates in 30-day steps — 3 mg to start, then 7 mg, then 14 mg if more glycemic control is needed — and the label ties the bulk of the gastrointestinal reports to those transitions rather than to the drug in general. The European product information for oral semaglutide says the same thing in its own words: most events were mild to moderate and of short duration, and were reported more frequently during the first months of treatment.

That does not promise anyone a smooth week four. It does mean that "worse after the step-up" is an expected shape rather than a mystery, and that the timing of a symptom relative to a dose change is clinically informative — which is why it is worth being able to state it precisely.

Discontinuation followed the same gradient: 8% of patients on 14 mg and 4% on 7 mg stopped treatment because of gastrointestinal adverse reactions, against 1% on placebo.

One practical note that belongs here rather than in a symptom list: the morning rules exist partly because absorption is fragile, and taking the tablet incorrectly does not make it gentler — it makes it less absorbed. The routine is walked through in the 30-minute wait, step by step.

What to do about the nausea

The label does not prescribe a nausea strategy, and neither will this page. What it does do is bound the question: the tablet must be swallowed whole with no more than 4 ounces of plain water on an empty stomach, and nothing may be eaten or drunk for at least 30 minutes. That rules out most of the folk remedies people reach for — ginger tea with the pill, food to "cushion" it, a bigger glass of water.

What remains inside the rules is what happens after the 30 minutes, and that is genuinely yours to shape. We wrote up what the label restricts at the table — including the perhaps surprising fact that the label restricts far less about food than the internet believes, and far more about timing.

If nausea, vomiting or diarrhea is severe or persistent, the relevant risk is not discomfort but dehydration; see the acute kidney injury note below.

"It got worse two days after the step-up" is a useful sentence. "Sometime last month" is not. Takely keeps the dose you took, the date, and a note on how the morning went on one timeline. Open Takely in your browser →

The boxed warning and the contraindications

Rybelsus carries a boxed warning about thyroid C-cell tumors. In the label's words: in rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and it is unknown whether the tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of the rodent finding has not been determined.

The label pairs that with a contraindication rather than a monitoring plan, because it notes that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with these tablets.

Rybelsus is contraindicated in patients with:

a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in the formulation.

The label instructs that patients be counselled about symptoms of thyroid tumors — a mass in the neck, dysphagia, dyspnea, persistent hoarseness.

The nine warnings and precautions

Section 5 of the label runs to nine subsections. This is the list, in order, with the one-line version of what each is about. It is a map of what to raise, not a checklist to self-assess against.

#	Warning	In one line
5.1	Risk of thyroid C-cell tumors	The boxed warning, restated
5.2	Acute pancreatitis	Persistent severe abdominal pain, sometimes with vomiting
5.3	Diabetic retinopathy complications	Rapid improvement in glucose control can coincide with worsening retinopathy
5.4	Hypoglycemia with insulin secretagogues or insulin	The risk lives in the combination, not in Rybelsus alone
5.5	Acute kidney injury due to volume depletion	The route runs through vomiting and diarrhea
5.6	Severe gastrointestinal adverse reactions	Not recommended in patients with severe gastroparesis
5.7	Hypersensitivity reactions	Anaphylaxis and angioedema have been reported
5.8	Acute gallbladder disease	Gallstones and cholecystitis
5.9	Pulmonary aspiration during general anesthesia or deep sedation	Delayed gastric emptying means the stomach may not be empty when a procedure assumes it is

Three of those repay a second look.

Acute kidney injury. The label reports postmarketing cases, some requiring hemodialysis, and notes that the majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. This is the mechanism by which a "common" side effect becomes a serious one, and it is the reason severe or prolonged vomiting and diarrhea are worth a call rather than a wait.

Aspiration under anesthesia. If you have surgery, a colonoscopy, dental work under sedation, or any procedure involving general anesthesia or deep sedation scheduled, the team needs to know you are taking a GLP-1 receptor agonist. The preoperative fasting instruction was written for a stomach that empties at a normal rate.

Hypoglycemia. Semaglutide stimulates insulin release in the presence of elevated blood glucose. The label's concern is the combination: patients taking these tablets with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia.

Long-term side effects: what four years of follow-up showed

"Long-term side effects of Rybelsus" is a common search and it has a partial answer, which is better than the confident ones circulating.

The longest exposure dataset in the label is a four-year cardiovascular outcomes trial in which 4,825 patients were randomized to semaglutide tablets, with a median follow-up of 49.6 months. Safety collection there was deliberately narrow — serious adverse events including death, adverse events leading to discontinuation, and adverse events of special interest. In that trial, study drug was permanently discontinued due to an adverse event in 15.5% of patients on semaglutide tablets versus 11.6% on placebo.

Gallbladder events in that trial: cholelithiasis reported in 1.1% and cholecystitis in 1.1% with 14 mg dosing.

Pancreatitis, across the pooled placebo- and active-controlled trials: reported as a serious adverse event in 6 semaglutide-tablet-treated patients (0.1 events per 100 patient-years) versus 1 comparator-treated patient.

Diabetic retinopathy-related adverse reactions in that same pool: 4.2% with semaglutide tablets and 3.8% with comparator. The label's separate retinopathy warning draws on a cardiovascular outcomes trial of semaglutide injection, where diabetic retinopathy complications occurred in 3% versus 1.8% on placebo, with a larger absolute increase among patients who already had retinopathy at baseline.

What no source can give you is a 10-year table, because oral semaglutide has not been on the market that long. Anyone presenting one is extrapolating.

Reactions that only surfaced after approval

Section 6.2 of the label collects reports from post-approval use. These are voluntary reports from a population of uncertain size, so frequency cannot be estimated and causality cannot be established — but they are the closest thing to a list of what turned up once millions of people took the drug rather than a few thousand trial participants.

Gastrointestinal: acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death; ileus; intestinal obstruction; severe constipation including fecal impaction
Hypersensitivity: anaphylaxis, angioedema, rash, urticaria
Hepatobiliary: cholecystitis, cholelithiasis requiring cholecystectomy
Nervous system: dizziness, dysesthesia, dysgeusia, headache
Pulmonary: aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation
Renal: acute kidney injury
Skin and subcutaneous tissue: alopecia

Whose numbers these are

Every figure above comes from the FDA label that Rybelsus now shares with Ozempic tablets. That matters for two reasons.

First, the label covers oral semaglutide approved for type 2 diabetes. The Wegovy tablet is the same molecule approved for a different indication at different strengths, and its adverse-reaction tables come from a different trial in a different population — which is why they should not be read across. That comparison is laid out in how Rybelsus and the Wegovy pill differ.

Second, labels are national documents. Japan's package insert for the same tablet has no boxed warning section at all and instead opens at contraindications, lists four serious adverse reactions with its own frequency bands, and puts weight loss in the adverse-reaction table rather than anywhere near the indication. If that is the label that applies to you, we wrote the Japanese label's version of the same list.

The one thing worth writing down

If you take one operational idea from this page, take this: the label ties most gastrointestinal reports to dose escalation, so the date of your last dose change is the single most useful thing in your own record.

It is also the thing nobody remembers. Three months in, "the nausea started around when I went up" is not a fact anyone can act on; "I moved to 14 mg on the 3rd and the nausea started on the 5th" is. The same goes for the reverse — a symptom that predates a step-up is telling you something different.

That is the whole reason Takely exists in the shape it does: log the dose and the day together, keep a one-line note about how the morning went, and the timeline assembles itself. Nothing leaves your browser, and there is nothing to fill in beyond a tap.

Frequently asked questions

What are the most common side effects of Rybelsus?

In the label's placebo-controlled pool: nausea (20% at 14 mg, 11% at 7 mg versus 6% on placebo), abdominal pain, diarrhea, decreased appetite, vomiting and constipation. Gastrointestinal reactions as a group occurred in 41% of patients on 14 mg, 32% on 7 mg and 21% on placebo.

How long do Rybelsus side effects last?

The label does not give a duration. It states that the majority of nausea, vomiting and diarrhea reports occurred during dose escalation, and the European product information describes most events as mild to moderate, of short duration, and more frequent during the first months of treatment. That is a pattern across trial populations, not a forecast for one person — what your own course looks like is a question for your prescriber.

What are the long-term side effects of Rybelsus?

The longest dataset in the label is a four-year cardiovascular outcomes trial with a median follow-up of 49.6 months, in which 15.5% of patients on semaglutide tablets discontinued due to an adverse event versus 11.6% on placebo. Gallbladder events, pancreatitis and diabetic retinopathy figures are reported separately. Data beyond that horizon does not yet exist for oral semaglutide.

Does Rybelsus cause weight loss as a side effect?

The US label lists decreased appetite as an adverse reaction (9% at 14 mg, 6% at 7 mg, 1% placebo). Rybelsus is approved to improve glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular event risk in adults with type 2 diabetes at high risk — weight management is not among its approved uses, and this page makes no claim about weight outcomes.

Which Rybelsus side effects mean I should call someone?

The label's serious categories include persistent severe abdominal pain, sometimes with vomiting (pancreatitis); severe or prolonged vomiting and diarrhea, because of the dehydration route to acute kidney injury; signs of a hypersensitivity reaction such as swelling or difficulty breathing; and symptoms of gallbladder disease. This is not a triage tool — if something worries you, contact your clinician or emergency services rather than a web page.

Do the side effects get worse at 14 mg than at 7 mg?

The frequencies in the label are higher at 14 mg for nausea (20% versus 11%), decreased appetite (9% versus 6%) and vomiting (8% versus 6%), and gastrointestinal reactions overall (41% versus 32%). Constipation was slightly lower at 14 mg. Whether and when a dose changes is your prescriber's decision.

Does taking Rybelsus with food reduce nausea?

Taking it with food is not an option the label leaves open: the tablet must be taken on an empty stomach with up to 4 ounces of plain water, and food, other drinks and other oral medicines must wait at least 30 minutes. Eating sooner reduces absorption rather than softening the drug.

Do I need to tell a surgeon or dentist that I take Rybelsus?

Yes. The label carries a warning about pulmonary aspiration during general anesthesia or deep sedation, because delayed gastric emptying raises the risk of residual gastric contents despite preoperative fasting.

Primary sources and further reading

Labels are revised. Everything on this page was checked against the sources above on 11 August 2026. Check the current label and ask your clinician or pharmacist about your own prescription.